Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

7MM Systemic Lupus Erythematosus and Lupus Nephritis Drug Market Analysis & Forecast 2024-2034: Future SLE and LN Players Competition, High Unmet Need for Steroid-sparing Treatments

globenewswire.com
ABBV AbbVie's drug, Humira (adalimumab), is a biologic therapy used for lupus. The article mentions the growth of biologic therapies in the lupus market, but also the emergence of biosimilars and high costs of new treatments, creating a mixed outlook. GSK GSK's drug, Benlysta (belimumab), is a key biologic therapy for lupus. The article notes its role in the market but also highlights the threat of biosimilars and the high cost of new pipeline drugs, suggesting a competitive and evolving landscape. AZN AstraZeneca's drug, Saphnelo (anifrolumab), is mentioned as a biologic therapy for lupus. The article points to its market presence but also the challenges from biosimilars and the high cost of novel treatments, indicating a complex market dynamic. GILD Gilead Sciences is involved in the lupus market with drugs like Gazyva/Gazyvaro (obinutuzumab) and potentially Rituximab. The article discusses the growth in biologic therapies but also the competitive pressures from biosimilars and high treatment costs. REGN While not explicitly mentioned, Regeneron has been involved in lupus research and development. The article's focus on unmet needs, pipeline drugs, and competition in the SLE/LN market suggests potential opportunities and challenges for companies like Regeneron.

7MM Systemic Lupus Erythematosus and Lupus Nephritis Drug Market Analysis & Forecast 2024-2034: Future SLE and LN Players Competition, High Unmet Need for Steroid-sparing Treatments Dublin, April 10, 2026 (GLOBE NEWSWIRE) -- The "Systemic Lupus Erythematosus and Lupus Nephritis: Seven-Market Drug Forecast and Market Analysis" report has been added to ResearchAndMarkets.com's offering.

This report covers the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends.

Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the Systemic Lupus Erythematosus and Lupus Nephritis market. The base year of the sales forecast model is 2024, and the forecast period is 2024-2034.

The analyst estimated that the SLE and LN market was $2.4 billion across the 7MM in 2024, increasing to $5.9 billion by 2034 at a compound annual growth rate (CAGR) of 9.6%. This growth was driven by the launch of ten late-stage pipeline agents entering a market previously dominated by the off-label use of generic immunosuppressants, anti-malarials, and corticosteroids, offering a significant improvement in safety and efficacy.

However, the market is expected to face significant barriers to its growth, most notably the entry of biosimilars such as belimumab and anifrolumab. And the slow adoption rate of pipeline therapeutics, due to the high annual cost of treatment associated with them.

Report Scope

Reasons to Buy

Key Topics Covered:

1 Systemic Lupus Erythematosus and Lupus Nephritis: Executive Summary

1.1 SLE market to significantly increase during the forecast period 2024-34

1.2 R&D strategies for the lupus market

1.3 High unmet need for steroid-sparing treatments that can reduce infection risk

1.4 Future SLE and LN players competition

1.5 Pipeline assessment

1.6 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Prognosis

3.3 Classification or staging systems

3.3.1 SLE classification

3.3.2 LN classification

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 7MM forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of SLE

4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of SLE by severity

4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of LN

4.4.6 Diagnosed prevalent cases of LN by class

4.5 Epidemiological forecast for diagnosed prevalent cases of SLE (2024-34)

4.5.1 Diagnosed prevalent cases of SLE

4.5.2 Age-specific diagnosed prevalent cases of SLE

4.5.3 Sex-specific diagnosed prevalent cases of SLE

4.5.4 Diagnosed prevalent cases of SLE by severity

4.5.5 Diagnosed prevalent cases of LN

4.5.6 Age-specific diagnosed prevalent cases of LN

4.5.7 Sex-specific diagnosed prevalent cases of LN

4.5.8 Diagnosed prevalent cases of LN by class

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 Limitations of the analysis

4.6.3 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

5.2 Treatment overview

5.3 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

6.2 SOC therapies in lupus

6.2.1 Antimalarials

6.2.2 Steroids

6.2.3 Immunosuppressive agents

6.3 Biologic therapies in lupus

6.3.1 Benlysta (belimumab)

6.3.2 Saphnelo (anifrolumab)

6.3.3 Gazyva/Gazyvaro (obinutuzumab)

6.3.4 Rituximab

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 More efficacious therapies and steroid-free treatment

7.3 Infection prevention

7.4 Improving patient compliance

7.5 Development of biomarkers for lupus disease activity

8 R&D Strategies

8.1 Overview

8.1.1 Novel MoAs

8.1.2 Label Expansion and Reformulation

8.2 Clinical trial design

8.2.1 Design overview

8.2.2 Patient populations

8.2.3 CAR-T clinical trials

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers - global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

Companies Featured

For more information about this report visit https://www.researchandmarkets.com/r/rnt7d7

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.